Servier signed a worldwide licensing agreement with Black Diamond Therapeutics for its small molecule solid tumour therapeutic, BDTX-4933.
The therapeutic is suitable for patients with RAF/RAS mutations, and is designed to address the unmet needs of this population.
Under the terms of the agreement, Servier will be responsible for the development and global commercialisation of BDTX-4933 across a range of indications.
The pharmaceutical company will begin by commercialising the product for by patients with non-small cell lung cancer (NSCLC), but it will also explore the therapeutic's potential in other solid tumour indications.
Through the deal, Servier will pay Black Diamond Therapeutics $70m upfront — though the company will also be eligible to receive up to $710m in milestone payments related to development and sales.
BDTX-4933 is currently in Phase I development, and is being assessed in adults with recurrent advanced/metastatic cancers with BRAF, CRAF or NRAS mutations.
“Our partnership to develop BDTX-4933 is an important opportunity in targeted cancer therapies, as we believe we can serve more people by helping the right patients find the right treatment, at the right time,” said Claude Bertrand, Executive Vice-President of R&D at Servier.
“This agreement supports our mission to advance oral cancer therapies designed to give patients the opportunity for longer, healthier and more active lives,” said Mark Velleca, President and CEO of Black Diamond Therapeutics.
“Servier’s commitment to innovation and deep expertise in oncology make it an ideal partner for Black Diamond as we work to develop breakthrough cancer treatments.”